Focused Pharmacogenomics Panel
Test in Focus
Mayo Clinic Laboratories’ updated focused pharmacogenomics panel uses real-time, PCR testing for targeted genotyping of 10 genes with known associations to medications used to treat a variety of disorders across a spectrum of specialities. In this “A Test in Focus” episode of the "Answers From the Lab" podcast, Ann Moyer, M.D., Ph.D., explains how this innovative assay helps guide providers on choosing the best treatment option for their patients.
“The goal of this panel would be that it should be useful for patients that are either on many different medications or patients where the differential diagnosis is still rather broad, where it's difficult to decide which medication to put the patient on,” Dr. Moyer says “Because these drugs metabolize so many different medications, hopefully this is a panel that, once the patient has it ordered, it can be reused again and again, throughout their care, no matter what specialty they're seeing.”
By including both genotype and phenotype evaluation of those genes with a high level of evidence for metabolic associations to medications, the test enables detailed insights on patients’ genetic dispositions, Dr. Moyer says. “We tried to be really careful and cognizant about making sure that we include all of the alleles that are relevant for various patient populations throughout the world. And I think that makes our tests something that should be useful for years to come.”
Listen to learn more about how our focused pharmacogenomics panel can help guide treatment selection and improve treatment outcomes for patients.
Note: Podcasts will not playback on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.
Submit only 1 of the following specimens:
Lisa Rimsza, M.D., explains how Mayo Clinic Laboratories' unique PM3CX test can accurately determine subtypes of large B-cell lymphoma. Precise diagnosis is critical to choosing appropriate chemotherapy.
Patients with elevated LDL or "bad" cholesterol face even greater risk if their levels of small dense LDL cholesterol are also high. Vlad Vasile, M.D., Ph.D., and Leslie Donato, Ph.D., explain how Mayo Clinic Laboratories' sdLDL-c assay measures concentrations of the small dense LDL subtype, to better guide clinical care.
Identifying a precise genetic cause of hearing loss impacts clinical management. Nicole Boczek, Ph.D., and Melanie Meyer, M.S., CGC, explain how Mayo Clinic Laboratories' updated panel yields comprehensive results for optimal patient care.